Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study
Luis A. Díaz, Kai‐Keen Shiu, Tae‐Won Kim, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J.A. Punt, Denis Smith, Rocio García‐Carbonero, Manuel Benavides, Peter Gibbs, Christelle de la Fourchardière, Fernando Rivera, Elena Élez, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David R. Fogelman, Patricia Marinello, Thierry André
Topics & Concepts
PembrolizumabMicrosatellite instabilityColorectal cancerMedicineOncologyInternal medicineChemotherapyOpen labelDNA mismatch repairCancerMicrosatelliteRandomized controlled trialImmunotherapyBiologyGeneticsGeneAlleleGenetic factors in colorectal cancerCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies